BridgeBio Oncology Therapeutics (BBOT) Change in Account Payables (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Change in Account Payables for 3 years, with the latest figure at $10.7 million in Q1 2026.

• Quarterly Change in Account Payables rose 1889.76% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.3 million (changed N/A YoY) and the FY2025 annual result came in at -$1.8 million, down 173.66% from the prior year.
• Change in Account Payables advanced to $10.7 million in Q1 2026 per BBOT's latest filing, from -$2.4 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $10.7 million in Q1 2026 and troughed at -$2.4 million in Q4 2025.
• A 3-year average of $1.8 million and a median of $537626.0 in 2025 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2025 and 2026: Change in Account Payables slumped 223.63% in 2025, then soared 1889.76% in 2026.
• Over 3 years, Change in Account Payables stood at $2.0 million in 2024, then plunged by 223.63% to -$2.4 million in 2025, then jumped by 542.08% to $10.7 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $10.7 million, -$2.4 million, and $538252.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.